Plasmodium Falciparum Infection and Interference with Effective B Cell Memory
恶性疟原虫感染和对有效 B 细胞记忆的干扰
基本信息
- 批准号:8851512
- 负责人:
- 金额:$ 19.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-06-01 至 2017-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAffinityAntibodiesAntibody AffinityAntibody ResponseAntigensAntimalarialsAreaAvidityB-LymphocytesBindingBloodCellsCessation of lifeChemopreventionChildClinicalDataDefectDevelopmentDiseaseExhibitsExposure toFalciparum MalariaFlow CytometryFrequenciesHIVHealthHouseholdHumoral ImmunitiesImmune systemImmunityImmunoglobulin-Secreting CellsImmunologicsIndividualInfectionInterventionLabelLaboratoriesLeadLifeMaintenanceMalariaMeasuresMemoryMemory B-LymphocyteMethodsMicroscopyMorbidity - disease rateOutcomeParasitemiaParasitesPhenotypePlasmodium falciparumPositioning AttributeReceptors, Antigen, B-CellResearch InfrastructureSamplingSerologicalSiteSpecificityStagingSurfaceTestingTimeUgandaacquired immunitybasecohortdensitydesignexperiencemalaria transmissionmortalitypathogenperipheral bloodprematurepreventresponsetransmission processvaccine-induced immunity
项目摘要
DESCRIPTION (provided by applicant): Naturally acquired immunity is critical in modulating morbidity and mortality from falciparum malaria in endemic areas, where some individuals are infected hundreds of times per year. Humoral responses to Plasmodium falciparum (Pf) are a critical component of this immunity, and Pf-specific memory B cells (MBCs) are likely important in the development and maintenance of an effective response. Unfortunately, protection from clinical disease takes many years to develop, during which time children living in endemic areas experience multiple episodes of symptomatic malaria, resulting in over 1 million deaths annually. Why does antimalarial immunity develop so slowly? One potential explanation is that Pf infection interferes with the development of effective B cell memory. An atypical phenotype of MBC, exhibiting evidence for lower affinity maturation and less capacity for differentiation into antibody secreting cells, has recently been described in the blood of HIV infected subjects. Recent studies have demonstrated that people living in malaria endemic areas have elevated frequencies of similar atypical MBCs, but the relationship between Pf exposure and frequencies of atypical MBCs has not been investigated in detail. Moreover, it is unclear what the consequences of these cells are in malaria infected individuals. We hypothesize that frequent exposure to Pf results in the selective diversion of Pf-specific B cells into an atypical MBC phenotype, delaying the acquisition of protective immunity to Pf. We are in a unique position to test this hypothesis, with access to a well characterized cohort of subjects living in an area of high but heterogeneous malaria transmission intensity and established laboratory infrastructure. Pf transmission intensity at our site in Tororo, Uganda ranks among the highest in the world, and preliminary data from this site suggest that affinity of Pf-specific antibody responses may be compromised in this setting. We will test our hypothesis with the following Specific Aims: 1) To measure the association between Pf exposure and enrichment of atypical memory B cells in children living in a high transmission region of Uganda.; and 2) To measure the association between enrichment of atypical memory B cells and serological and parasitological evidence of protective humoral immunity to malaria. We anticipate this study will show that increased exposure to Pf is associated with increased defects in B cell memory, characterized by higher proportions of Pf-specific MBCs showing an atypical phenotype and evidence of reduced Pf-specific antibody affinity and ability to control blood stage parasites. If so, counter to prevailig notions that malaria control efforts will delay the acquisition of immunity, strategies designed to
reduce exposure may have a positive impact on immunity. In addition, methods to characterize Pf-specific B cells developed in this study will have broad application for investigating humoral immunity to Pf.
描述(由申请人提供):自然获得的免疫力对于调节流行地区恶性疟疾的发病率和死亡率至关重要,那里有些人每年被感染数百次。对恶性疟原虫(PF)的体液反应是这种免疫力的关键组成部分,而PF特异性记忆B细胞(MBC)可能在开发和维持有效反应中很重要。不幸的是,免受临床疾病的保护需要多年的发展,在此期间,生活在地方性地区的儿童经历了多次症状性疟疾,每年导致超过100万人死亡。为什么抗疟疾的免疫力如此缓慢?一种潜在的解释是,PF感染会干扰有效B细胞记忆的发展。最近在HIV感染受试者的血液中描述了MBC的非典型表型,该表型表现出较低的亲和力成熟和较少分化为抗体分泌细胞的能力的证据。最近的研究表明,居住在疟疾地区的人们的频率升高了相似的非典型MBC,但是尚未详细研究PF暴露与非典型MBC的频率之间的关系。此外,尚不清楚这些细胞在受疟疾感染的个体中的后果。我们假设频繁暴露于PF会导致PF特异性B细胞的选择性转移成非典型的MBC表型,从而延迟了对PF的保护性免疫的获取。我们处于检验这一假设的独特位置,访问居住在高但异质的疟疾传播强度和已建立的实验室基础设施领域的受试者的众多受试者中。乌干达的PF传播强度在世界上排名最高,该站点的初步数据表明,在这种情况下,PF特异性抗体反应的亲和力可能会受到损害。我们将以以下特定目的检验我们的假设:1)在乌干达高传播地区的儿童中,PF暴露与非典型记忆B细胞的富集之间的关联。 2)衡量非典型记忆B细胞富集与保护性体液对疟疾的富集之间的关联。我们预计这项研究将表明,对PF的接触增加与B细胞记忆中的缺陷增加有关,其特征是较高比例的PF特异性MBC,表现出非典型表型,以及PF特异性抗体亲和力降低的证据和控制血液阶段寄生虫的能力。如果是这样,请与盛行的观念相反,即疟疾控制努力将延迟获得免疫的获得,旨在的策略
减少暴露可能会对免疫产生积极影响。此外,在本研究中开发的PF特异性B细胞表征的方法将在研究对PF的体液免疫力方面具有广泛的应用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bryan R Greenhouse其他文献
Bryan R Greenhouse的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bryan R Greenhouse', 18)}}的其他基金
Drivers of strain-specific and strain-transcendent antimalarial immunity in childhood
儿童时期菌株特异性和菌株超越性抗疟免疫的驱动因素
- 批准号:
10190800 - 财政年份:2020
- 资助金额:
$ 19.81万 - 项目类别:
Drivers of strain-specific and strain-transcendent antimalarial immunity in childhood
儿童时期菌株特异性和菌株超越性抗疟免疫的驱动因素
- 批准号:
10406294 - 财政年份:2020
- 资助金额:
$ 19.81万 - 项目类别:
Drivers of strain-specific and strain-transcendent antimalarial immunity in childhood
儿童时期菌株特异性和菌株超越性抗疟免疫的驱动因素
- 批准号:
10630290 - 财政年份:2020
- 资助金额:
$ 19.81万 - 项目类别:
Mentoring translational scientists in international infectious disease research
指导国际传染病研究中的转化科学家
- 批准号:
10320014 - 财政年份:2019
- 资助金额:
$ 19.81万 - 项目类别:
Mentoring translational scientists in international infectious disease research
指导国际传染病研究中的转化科学家
- 批准号:
10534671 - 财政年份:2019
- 资助金额:
$ 19.81万 - 项目类别:
Novel serologic assays of P. falciparum exposure for improved surveillance in control and elimination.
恶性疟原虫暴露的新型血清学检测可改善控制和消除监测。
- 批准号:
9107071 - 财政年份:2016
- 资助金额:
$ 19.81万 - 项目类别:
Plasmodium Falciparum Infection and Interference with Effective B Cell Memory
恶性疟原虫感染和对有效 B 细胞记忆的干扰
- 批准号:
8701920 - 财政年份:2014
- 资助金额:
$ 19.81万 - 项目类别:
Translational Studies of Plasmodium Falciparum Infection Dynamics
恶性疟原虫感染动力学的转化研究
- 批准号:
8110476 - 财政年份:2008
- 资助金额:
$ 19.81万 - 项目类别:
Translational Studies of Plasmodium Falciparum Infection Dynamics
恶性疟原虫感染动力学的转化研究
- 批准号:
8321055 - 财政年份:2008
- 资助金额:
$ 19.81万 - 项目类别:
Translational Studies of Plasmodium Falciparum Infection Dynamics
恶性疟原虫感染动力学的转化研究
- 批准号:
7676157 - 财政年份:2008
- 资助金额:
$ 19.81万 - 项目类别:
相似国自然基金
基于计算生物学技术小分子农兽药残留物驼源单域抗体虚拟筛选与亲和力成熟 -以内蒙古阿拉善双峰驼为例
- 批准号:32360190
- 批准年份:2023
- 资助金额:34 万元
- 项目类别:地区科学基金项目
框架核酸多价人工抗体增强靶细胞亲和力用于耐药性肿瘤治疗
- 批准号:32301185
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
中国年轻女性接种不同剂次国产双价HPV16/18疫苗的特异性抗体亲和力及细胞免疫反应研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
中国年轻女性接种不同剂次国产双价HPV16/18疫苗的特异性抗体亲和力及细胞免疫反应研究
- 批准号:82273723
- 批准年份:2022
- 资助金额:52.00 万元
- 项目类别:面上项目
基于酵母展示与自体持续突变的纳米抗体快速亲和力成熟技术研究
- 批准号:82204046
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Immunomodulatory ligand B7-1 targets p75 neurotrophin receptor in neurodegeneration
免疫调节配体 B7-1 在神经变性中靶向 p75 神经营养蛋白受体
- 批准号:
10660332 - 财政年份:2023
- 资助金额:
$ 19.81万 - 项目类别:
Host Defense Small Molecule Development for COVID-19 Treatment by Targeting Lysosome
通过靶向溶酶体治疗 COVID-19 的宿主防御小分子开发
- 批准号:
10735492 - 财政年份:2023
- 资助金额:
$ 19.81万 - 项目类别:
Targeting HNF4-induced thrombo-inflammation in Chagas disease
针对恰加斯病中 HNF4 诱导的血栓炎症
- 批准号:
10727268 - 财政年份:2023
- 资助金额:
$ 19.81万 - 项目类别:
Broadly neutralizing SARS-CoV-2 peptidic knobs
广泛中和 SARS-CoV-2 肽旋钮
- 批准号:
10735902 - 财政年份:2023
- 资助金额:
$ 19.81万 - 项目类别:
Development of antigen multimers for CAR T cell detection and functional profiling
开发用于 CAR T 细胞检测和功能分析的抗原多聚体
- 批准号:
10741209 - 财政年份:2023
- 资助金额:
$ 19.81万 - 项目类别: